3-Benzyl-buttersaeure-amid | 20568-07-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Benzyl-buttersaeure-amid
• 英文别名: (+/-)-3-methyl-4-phenyl-butyric acid amide；(+/-)-3-Methyl-4-phenyl-buttersaeure-amid；3-Methyl-4-phenylbutanamide
• CAS: 20568-07-4
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: UGUYCFCHAOHXOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 ammonium hydroxide 作用下， 生成 3-Benzyl-buttersaeure-amid
  参考文献：
  名称：

  MOLECULAR REARRANGEMENTS INVOLVING OPTICALLY ACTIVE RADICALS. VIII. THE WOLFF REARRANGEMENT OF OPTICALLY ACTIVE DIAZOKETONES

  摘要：

  DOI：

  10.1021/jo01209a009

文献信息

• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• Process for polymerizing epsilon-caprolactam
  申请人：UNITIKA LTD.

  公开号：EP0522533A1

  公开（公告）日：1993-01-13

  A process for forming an ultra-high molecular weight nylon 6 by polymerizing ε-caprolactam, which comprises heating substantially anhydrous ε-caprolactam at a temperature of from 100 to 200°C in the presence of (a) a main catalyst selected from a Grignard compound and a halogenated magnesium lactamate, (b) a co-catalyst selected from an acyl lactam compound and an isocyanic acid ester and (c) at least one activator selected from the group consisting of amides, sulfoxides, thioethers and phosphoric esters. According to this inventive process, an ultra-high molecular weight nylon 6 can be produced within a short period of time, making use of industrially advantageous compounds which are stable in air, hardly dangerous and inexpensive. Being free from cross-linkings, the ultra-high molecular weight nylon 6 obtained by the process of this invention is soluble in various solvents and is useful as a starting material for the production of high strength and high modulus materials.

  一种通过聚合ε-己内酰胺形成超高分子量尼龙 6 的工艺，包括在 100 至 200°C 的温度下，在以下物质存在的情况下加热基本无水的ε-己内酰胺：(a) 主催化剂，选自格氏化合物和卤代内酰胺镁、(b) 选自酰基内酰胺化合物和异氰酸酯的助催化剂，以及 (c) 至少一种选自酰胺、硫醚、硫醚和磷酸酯的活化剂。根据本发明的工艺，可以在短时间内生产出超高分子量尼龙 6，利用的是在空气中稳定、几乎没有危险且价格低廉的工业优势化合物。由于不存在交联，通过本发明工艺获得的超高分子量尼龙 6 可溶于各种溶剂，可用作生产高强度和高模量材料的起始材料。
• INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS
  申请人：AstraZeneca AB

  公开号：EP2102169A1

  公开（公告）日：2009-09-23
• ENVIRONMENTALLY-FRIENDLY HYDROAZIDATION OF OLEFINS
  申请人：Georgia State University Research Foundation, Inc.

  公开号：EP3784660A1

  公开（公告）日：2021-03-03
• US5245004A
  申请人：——

  公开号：US5245004A

  公开（公告）日：1993-09-14